CA-SCIENTIST.COM
Scientist.com, the pharma industry’s leading research marketplace, and PhenoVista, a life sciences services company developing and implementing multiplexed, high content imaging-based phenotypic assays for target validation, lead optimization, and mechanism of action studies, have launched the biotech industry’s first digital eShop for exploring and purchasing phenotypic studies.
The digital storefront makes it easy for scientists to design complex research projects, get feedback from PhenoVista’s experts, determine pricing, and then purchase and manage projects. What previously could require hours of face-to-face meetings or video calls can now be accomplished online in much less time. The Shopify-like virtual store was created by Scientist.com and is designed to make it as easy to purchase complex assay services as it is to buy products and reagents.
“Today, almost half of the $240B spent annually on drug research is performed by companies like PhenoVista that offer highly technical and specialized custom assay services,” said Kevin Lustig, PhD, CEO and Founder at Scientist.com. “With the launch of PhenoVista’s online store, researchers get more immediate access to their services and expertise, allowing them to accelerate crucial experiments and benefit from the use of data-rich phenotypic studies.”
There are significant advantages offered by high-plex phenotypic studies across the entire R&D workflow as compared to conventional, low-plex in vitro assays.
“High-stakes decision making is at the heart of R&D, and uncertainty about targets, mechanisms of action, and whether to advance or abandon candidate compounds is the norm,” said James G. Evans, CEO and Founder of PhenoVista. “With expertise in high-content imaging-based phenotypic studies, we deliver the biological insights and high-quality data needed to inform and de-risk these decisions. We are excited to leverage the marketplace experience established by Scientist.com to create our virtual storefront and bring added convenience to researchers in the biotech industry.”
The virtual storefront can be accessed at https://store.phenovista.com/.
About Scientist.com
Scientist.com is a privately held San Diego-based company on a mission to make it faster and cheaper to discover new medicines. At its heart is an AI-powered marketplace that helps drug researchers use innovative technologies to rapidly translate their ideas into actionable data. Through Scientist.com, scientists communicate directly with research experts at over 4,000 global laboratories to design and execute complex research experiments. Visit scientist.com to learn more.
Join Scientist.com on social media: LinkedIn, Twitter, YouTube, Facebook and Instagram.
About PhenoVista
Founded in 2014, PhenoVista is a leader in the development and implementation of multiplexed, high content imaging-based phenotypic assays for biopharmaceutical clients. These assays deliver the high-quality, quantitative data needed to inform and de-risk critical R&D decisions with greater confidence. Clients gain access to novel insights related to the complex biology underlying target validation, therapeutic delivery, efficacy and safety, cytotoxicity, and mechanisms of action, increasing the likelihood of success of first-in-class drug candidates. To learn more, visit our website www.phenovista.com or see us on LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240214355636/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Agendia Announces NCCN Guideline Update Recognizing MammaPrint to Guide Personalized Anthracycline Use in HR+/HER2- Early‑Stage Breast Cancer20.1.2026 13:00:00 CET | Press release
Update based on real-world evidence from the FLEX Study presented at the 2025 San Antonio Breast Cancer Symposium Agendia, Inc., a leader in precision oncology for breast cancer, today announced that the updated NCCN Clinical Practice Guidelines in Oncology1 (NCCN Guidelines®) now recognize that MammaPrint® + BluePrint® can help identify a subset of hormone receptor positive, HER2-negative (HR+/HER2–) early-stage breast cancer (EBC) patients most likely to benefit from anthracycline-based chemotherapy. “I am delighted that oncologists finally have a way to identify HR+/HER2- early breast cancer patients who will benefit from anthracycline therapy," said Joyce A. O’Shaughnessy, M.D., principal investigator for the FLEX Study. “I think the biologic rationale and the data underpinning the observation that High Risk 2 Luminal (by BluePrint) breast cancer patients benefit from anthracycline therapy are quite strong.” The updated NCCN Guidelines are based on a three-year analysis of outcomes
Cargill Wins 2026 BIG Innovation Award20.1.2026 13:00:00 CET | Press release
The company was honored as a Top Innovator for large-scale AI-and-data-driven innovation advancing food security, operational excellence and resilient food systems Cargill today announced it has been named a winner in the 2026 BIG Innovation Awards by the Business Intelligence Group and designated as a Top 10 Innovator, recognizing the company’s disciplined approach to innovation across the global food and agriculture system. Cargill was honored in the Innovative Organizations category, alongside a cohort of 159 companies, products and leaders that are transforming industries through applied innovation and measurable real-world impact. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260120109897/en/ Cargill has been named a winner in the 2026 BIG Innovation Awards by the Business Intelligence Group and designated as a Top 10 Innovator, recognizing the company’s disciplined approach to innovation across the global food and agr
Armis Helps Italian Grocery Retailer Multicedi Strengthen Cyber Resilience20.1.2026 13:00:00 CET | Press release
Armis Centrix™ identified that 10-15% of connected assets across the organization’s network were previously unaccounted for, introducing cyber risk Armis, the cyber exposure management & security company, today announced that Multicedi, one of the leading grocery retail groups in Central and Southern Italy, is using Armis Centrix™, Armis’ Cyber Exposure Management Platform, to strengthen its cybersecurity posture. “Before introducing Armis, critical issues were addressed only when malfunctions or abnormal events had already occurred,” said Livio De Prisco, Director of Information Systems at Multicedi. “With Armis Centrix™, the approach has completely changed: rather than responding reactively, the company now has a real-time view of its entire device fleet and can manage it proactively. We can detect devices that have been added to the network, prioritize risks based on their criticality, and define action plans and budgets consistent with our operational and regulatory requirements.”
TreviPay Launches Pay by Invoice for Issuers Enabled by Visa Credentials20.1.2026 13:00:00 CET | Press release
TreviPay’s Pay by Invoice solution enables Visa issuers and their business buyers to use Visa credentials for supplier payments to unlock new B2B opportunities TreviPay announces the launch of its Pay by Invoice solution for Visa-issuing banks, enabling issuers to capture a greater share of the $58 trillion North American B2B payments market. Through this collaboration with Visa, a world leader in digital payments, TreviPay’s order-to-cash automation technology combines with Visa’s commercial payment capabilities to help issuers move fragmented B2B spend into strategic, issuer-financed, invoice-based transactions. A Murphy Research study, found 26% of corporate payments are still made with checks or rely on manual legacy ACH processes. The study also shows 78% of global B2B buyers need customization or control in their payments and invoicing workflows, with 61% preferring to pay on net terms. Pay by Invoice helps banks meet these expectations by providing suppliers with early payment (
Philip Morris International Opens Dialogue on the Future of Human Cognition as a Defining Frontier in the Age of AI20.1.2026 11:03:00 CET | Press release
The paper calls for global debate to ensure AI enhances—rather than diminishes—uniquely human strengths in an increasingly automated world Philip Morris International Inc. (NYSE: PM) today released a new white paper, “Human Cognition: The Next Frontier?”, inviting leaders across business, policy, and academia to join a global conversation on the evolving role of human cognition as artificial intelligence transforms work, society, and the economy. The white paper explores how human capabilities such as - critical thinking, creativity and adaptability - are poised to become the “superskill” of the future, driving progress in an era of human-machine collaboration. As AI automates routine tasks and augments knowledge work, PMI argues that nurturing and protecting cognitive capacity will be essential for organizations seeking to remain resilient and relevant. Where once technology often automated labor-intensive jobs in the quest to improve productivity, now, as intelligent systems take on
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom